CRISPR Therapeutics AG CRSP 深 沪
等待开盘 12-03 09:30:00 美东时间
51.58
-0.590
-1.13%
华盛通- 最 高53.03
- 今 开52.43
- 成交量 141.64万股
- 最 低 51.20
- 昨 收 52.17
- 总市值 46.91亿
- 52周最高 78.48
- 市盈率 静 --
- 换手率 1.56%
- 52周最低 30.04
- 委 比 -52.27%
- 总股本 9095.04万
- 历史最高 220.20
- 量 比 0.67
- 振 幅 3.51%
- 历史最低 13.50
- 每 手 1
- 风险率 10.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Crispr Therapeutics pares loss amid takeover speculation
Crispr Therapeutics (CRSP) pared a loss amid some takeover speculation. There's speculation that a takeover bid for Crispr (CRSP) could be moving along as the potential buyer has hired an adviser to h...
12-02 00:51
Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $74
Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $82 to $74.
11-26 22:32
FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder
Arrowhead Pharmaceuticals won FDA approval for Redemplo (plozasiran), an siRNA drug reducing high triglycerides in adults with rare FCS.
11-19 02:07
Crispr Therapeutics gains amid takeover speculation
Crispr Therapeutics (CRSP) quickly rose 1.3% amid some takeover speculation. Crispr (CRSP) is said to have attracted takeover interest, according to traders, who cited a Betaville "uncooked' alert tha...
11-18 00:12
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
CRISPR Therapeutics Q3 EPS $(1.17) Beats $(1.24) Estimate, Sales $889.000K Miss $8.904M Estimate
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.24) by 5.26 percent. This is a 15.84 percent decrease over losses of $(1.01) per share
11-10 21:10
CRISPR Therapeutics Phase 1 CTX310 Trial Participants With Elevated Baseline Triglycerides, Showed Mean Reduction Of 60% In TG Observed At Therapeutic Doses
Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025--Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in circulating ANGPTL3
11-08 23:09
FDA Awards Second Batch of National Priority Vouchers
https://www.fda.gov/news-events/press-announcements/fda-awards-second-batch-national-priority-vouchers
11-07 02:55
